Stockscreener 앱 받기
86.35
1.14%
0.97
시간 외 거래:
86.00
-0.35
-0.41%
전일 마감가:
$85.38
열려 있는:
$85.46
하루 거래량:
1.99M
Relative Volume:
1.16
시가총액:
$42.71B
수익:
$9.93B
순이익/손실:
$1.12B
주가수익비율:
38.38
EPS:
2.25
순현금흐름:
$1.58B
1주 성능:
+0.24%
1개월 성능:
-10.44%
6개월 성능:
-2.81%
1년 성능:
-1.17%
1일 변동 폭
$85.09
$86.91
1주일 범위
$84.94
$87.64
52주 변동 폭
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
ALC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
86.35 | 42.61B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
555.75 | 194.50B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
173.82 | 49.39B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
245.12 | 36.00B | 5.02B | 1.31B | 1.56B | 8.91 |
|
COO
The Cooper Companies, Inc.
|
79.96 | 15.86B | 3.93B | 415.40M | 384.70M | 2.06 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-05-14 | 재확인 | BTIG Research | Buy |
| 2025-03-28 | 재확인 | Needham | Buy |
| 2025-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-24 | 재확인 | Needham | Buy |
| 2025-01-10 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | 재확인 | Needham | Buy |
| 2024-11-12 | 재확인 | Needham | Buy |
| 2024-10-10 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-10 | 개시 | Goldman | Buy |
| 2024-03-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | 개시 | Bernstein | Outperform |
| 2023-12-18 | 다운그레이드 | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | 업그레이드 | Societe Generale | Sell → Hold |
| 2022-12-22 | 개시 | Mizuho | Buy |
| 2022-11-17 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-08-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-05-13 | 재개 | Credit Suisse | Outperform |
| 2022-05-12 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | 개시 | Needham | Buy |
| 2022-03-11 | 개시 | BofA Securities | Buy |
| 2022-01-18 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 개시 | Oppenheimer | Perform |
| 2021-07-14 | 개시 | Deutsche Bank | Buy |
| 2021-05-06 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-03-22 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-11-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-07-06 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-07-06 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Argus | Hold → Buy |
| 2020-03-24 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-03-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-26 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-01-08 | 개시 | Argus | Hold |
| 2019-10-29 | 개시 | Stephens | Equal-Weight |
| 2019-08-21 | 재확인 | BofA/Merrill | Neutral |
| 2019-06-24 | 개시 | SVB Leerink | Mkt Perform |
| 2019-06-14 | 개시 | BTIG Research | Neutral |
| 2019-05-10 | 개시 | Robert W. Baird | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
모두보기
Alcon Inc 주식(ALC)의 최신 뉴스
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
US FDA approves Alcon's new dry-eye drug - Reuters
Alcon Stock Rises Following the FDA Approval of TRYPTYR - TradingView
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
WeMade Files Antitrust Complaint Against South Korea’s Major Crypto Exchanges - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Turkey Contact Lens MarketCompetition, Forecast & Opportunities to 2030, Featuring Tech Contactlens, Diafarma, Alcon Laboratories, Diplomat Optics, Hoya Turkiye, ZEISS Turkiye, Keralens & more - Yahoo
U.S. Ophthalmic Photocoagulator Growth Trends and Forecasts 2025-2032 - GlobeNewswire Inc.
FTC Requests More Information on Alcon's $430 Million Acquisition of Lensar - PYMNTS.com
FTC Probing Alcon's $430M Lensar Deal - Law360
Stifel Nicolaus Reaffirms Their Buy Rating on Alcon (ALC) - The Globe and Mail
Eye care product makers Alcon, LENSAR get second request from US FTC - MLex
Alcon (ALC) Receives Upgrade to Buy from Kepler Cheuvreux | ALC Stock News - GuruFocus
Alcon Inc. (NYSE:ALC) Q1 2025 Earnings Call Transcript - MSN
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy - GuruFocus
Alcon (ALC): A Key Partner in Lifecore's Revenue Growth Strategy | ALC Stock News - GuruFocus
Alcon (VTX:ALC) Strong Profits May Be Masking Some Underlying Issues - simplywall.st
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Alcon (ALC) - The Globe and Mail
Alcon's (VTX:ALC) Profits May Not Reveal Underlying Issues - Yahoo Finance
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating - Investing.com Canada
RBC Capital Adjusts Price Target for Alcon (ALC) While Maintaining Optimism | ALC Stock News - GuruFocus
Stifel maintains Alcon stock Buy rating, $100 target amid new drug launch - Investing.com Nigeria
Deutsche Bank Downgrades Alcon (ALC) Rating, Lowers Price Target | ALC Stock News - GuruFocus
Deutsche Bank cuts Alcon stock rating, lowers price target - Investing.com
Deutsche Bank cuts Alcon stock rating, lowers price target By Investing.com - Investing.com Nigeria
RBC cuts Alcon stock price target to CHF95, keeps Outperform rating By Investing.com - Investing.com South Africa
LENSAR Announces Merger with Alcon Research - TipRanks
Alcon updates 2025 sales growth target to 6%-7% driven by new product launches and tariff mitigation - MSN
Alcon stock target cut to $109 by Bernstein on Q2 outlook - Investing.com Nigeria
Alcon’s Earnings Call: Balancing Growth and Challenges - TipRanks
Alcon (ALC) Sees Notable Increase in Borrow Rate | ALC Stock New - GuruFocus
Alcon Revises Outlook As Swiss Market Stays Steady - Finimize
India Ophthalmic Devices Market Forecast Report 2025-2033, Competitive Analysis of Alcon, Bausch Health, Carl Zeiss, Meditec, Essilor, Hoya, Johnson & Johnson, Nidek, Topcon - Yahoo
Alcon Inc (ALC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.15%
0.20%
자본화:
|
볼륨(24시간):